We found that DYNLT1, IMMT, RAB2A, and SLC25A5 were tumor biomarkers to assess the prognosis of BRCA patients, and all of them were high-risk genes, and the parameters indicated that 4 genes would make the prognosis of BRCA poorer. Here, SLC25A5 is linked to neoplasm.